ANI Pharmaceuticals Inc (ANIP)vsTeva Pharma Industries Ltd ADR (TEVA)
ANIP
ANI Pharmaceuticals Inc
$70.19
-1.78%
HEALTHCARE · Cap: $1.64B
TEVA
Teva Pharma Industries Ltd ADR
$37.09
+2.04%
HEALTHCARE · Cap: $42.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 1670% more annual revenue ($17.32B vs $978.38M). ANIP leads profitability with a 11.1% profit margin vs 4.1%. TEVA appears more attractively valued with a PEG of 0.67. ANIP earns a higher WallStSmart Score of 76/100 (B+).
ANIP
Strong Buy76
out of 100
Grade: B+
TEVA
Hold49
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 191.1% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 25.9% year-over-year
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ANIP
The strongest argument for ANIP centers on EPS Growth, P/E Ratio, Price/Book. Revenue growth of 25.9% demonstrates continued momentum. PEG of 1.06 suggests the stock is reasonably priced for its growth.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : ANIP
The primary concerns for ANIP are Altman Z-Score, Market Cap.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
ANIP profiles as a growth stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.87 — expect wider price swings.
ANIP is growing revenue faster at 25.9% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Bottom Line
ANIP scores higher overall (76/100 vs 49/100) and 25.9% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ANI Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and Canada. The company is headquartered in Baudette, Minnesota.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?